SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

Nvidia is caught in a broad semiconductor and AI-stock selloff as traders worry that post-election opposition and possible data-center restrictions could slow AI infrastructure spending, with concerns about crowded valuations and forced liquidations adding pressure. The community is split between viewing the decline as an overreaction and buying the dip, and seeing it as the start of a deeper AI-trade unwind.

SPDR S&P 500 ETF TRUST - SPDR S&P 500 ETF Trust

A steep broad-market selloff has sparked debate over fears that Democratic gains could bring tighter AI oversight and slow data-center investment, alongside concerns about stretched valuations and forced selling. Traders disagree on whether the drop marks a deeper correction or an overreaction, with some looking for a rebound and others expecting more downside.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

QQQ is drawing attention after a steep tech-led selloff, with traders linking the pressure to fears that a Democratic-controlled Congress could constrain AI and data-center expansion. Some view the move as an overreaction and buying opportunity, while others point to AI valuation concerns and possible forced selling as reasons for caution; the policy impact remains uncertain.

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Cloud Memory Business Unit (CMBU), Core Data Center Business Unit (CDBU), Mobile and Client Business Unit (MCBU), and Automotive and Embedded Business Unit (AEBU). The CMBU segment focuses on memory solutions for large hyperscale cloud customers and High-Bandwidth Memory for all data center customers. The CDBU segment is involved in memory solutions for mid-tier cloud, enterprise, and OEM data center customers and storage solutions for all data center customers. The MCBU segment focuses on memory and storage solutions for the mobile and client segments. The AEBU segment is involved in memory and storage solutions for the automotive, industrial, and consumer segments. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

A broad semiconductor and AI-stock selloff, fueled by fears that Democratic control of Congress and calls to regulate or pause advanced AI could slow data-center investment, is driving attention to Micron. Traders are split between seeing an overreaction and buying the dip on continued memory demand, and warning that uncertainty around AI spending could mean further downside.

Sandisk Corp. engages in the development, manufacture, and provision of storage devices and solutions based on NAND flash technology. Its products include solid state drives, memory cards, and USB flash drives. The company was founded on February 5, 2024 and is headquartered in Milpitas, CA.

Sandisk Corp

A sharp semiconductor and AI-linked selloff, tied by traders to fears that Democratic control could bring tighter AI and data-center rules and slow infrastructure spending, is driving attention to SNDK. Bulls call the decline an overreaction and point to memory demand, while bears see an AI-trade unwind and further downside; some traders also blame broad deleveraging.

Advanced Micro Devices, Inc. engages in the semiconductor business. Its products include processors, accelerators, graphics, adaptive SoCs, FPGAs, and SOMs, and software, tools, and apps. The firm offers artificial intelligence, industries, workloads, and gaming solutions. The company was founded by W. J. Sanders III on May 1, 1969 and is headquartered in Santa Clara, CA.

Advanced Micro Devices Inc.

Advanced Micro Devices Inc

AMD is caught in a broad semiconductor and AI-stock selloff as traders fear a Democratic-controlled Congress could increase scrutiny of data centers and slow the AI buildout. The community is split between expecting further losses and viewing the drop as an overreaction, pointing to AMDs strong results and continued AI demand as reasons for optimism.

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bull 3X ETF

Direxion Daily Semiconductor Bull 3X Shares

SOXL is plunging alongside a sharp semiconductor and broader tech selloff, as traders debate fears of a slowdown in AI and data-center investmentsome linked to election-related policy concernsagainst the possibility of forced selling and leveraged-position unwinds. The steep decline has prompted panic and bearish calls, while other traders see an overreaction and are buying for a potential rebound; SOXLs 3x daily leverage amplifies the volatility.

ProShares Trust - ProShares UltraPro QQQ 3x Shares

ProShares UltraPro QQQ

A sharp Nasdaq and technology-stock selloff, amid concerns about AI spending and semiconductor weakness, has weighed on TQQQ, whose daily leverage amplifies index moves. Traders are divided between buying the oversold dip for a rebound and expecting further downside, with some pointing to heavier put activity as a sign of caution.

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Teslas sharp selloff is widely tied to traders concerns that the midterm election results could bring greater political scrutiny of Elon Musk and regulatory hurdles for a potential TeslaSpaceX merger, alongside a broader tech-market decline. The discussion is heavily bearish, though some traders view the drop as an oversold dip-buying opportunity; the merger and regulatory risks remain concerns rather than confirmed outcomes.

IREN Ltd. is a vertically integrated data center business powering the future of Bitcoin, AI and beyond with renewable energy. It is strategically located in renewable-rich, fiber-connected regions across the US and Canada. IREN’s large-scale, grid-connected facilities are purpose-built for the next generation of power-dense computing applications. The company was founded by Daniel Roberts and William Roberts on November 6, 2018, and is headquartered in Sydney, Australia.

IREN Ltd.

IREN Limited

IREN is under pressure amid reports of delays at its Texas data-center site tied to Microsoft, alongside a broad selloff in AI-infrastructure stocks and concerns about political and regulatory risks. Traders are divided between viewing the steep decline as a buying opportunity and fearing that execution issues or weak earnings guidance could deepen the selloff.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Here's Why Allarity Therapeutics, Inc. (ALLR) Is a Great 'Buy the Bottom' Stock Now

After losing some value lately, a hammer chart pattern has been formed for Allarity Therapeutics, Inc. (ALLR), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.

Are Medical Stocks Lagging  Allarity Therapeutics, Inc. (ALLR) This Year?

Here is how Allarity Therapeutics, Inc. (ALLR) and ANIXA BIOSCIENCES INC (ANIX) have performed compared to their sector so far this year.

Is Allarity Therapeutics, Inc. (ALLR) Stock Outpacing Its Medical Peers This Year?

Here is how Allarity Therapeutics, Inc. (ALLR) and Amgen (AMGN) have performed compared to their sector so far this year.

12 Health Care Stocks Moving In Monday's After-Market Session

Gainers

Catheter Precision (AMEX:VTAK) shares rose 78.2% to $1.55 during Monday's after-market session. The company's market cap stands at $2.2 million.
Allarity Therapeutics (NASDAQ:ALLR) stock increased byread more...

Is Allarity Therapeutics, Inc. (ALLR) Outperforming Other Medical Stocks This Year?

Here is how Allarity Therapeutics, Inc. (ALLR) and Alterity Therapeutics Limited - Sponsored ADR (ATHE) have performed compared to their sector so far this year.

Here is how Allarity Therapeutics, Inc. (ALLR) and Bioventus (BVS) have performed compared to their sector so far this year.

Are Medical Stocks Lagging  Bioventus (BVS) This Year?

Here is how Bioventus (BVS) and Allarity Therapeutics, Inc. (ALLR) have performed compared to their sector so far this year.

Why Did Allarity Therapeutics Stock Double In Value Today?

Equity

The company’s Stenoparib, an investigational treatment for patients with advanced ovarian cancer, was granted the Fast Track designation by the FDA.

ReShape Lifesciences, Allarity, Exact Sciences, CVS, AbbVie: 5 Health Care Stocks That Led Retail Message Growth Last Week

Speculation over an impending reverse merger, a Phase 2 trial announcement, comments about upcoming cancer screening tests, a  Medicare business deal, and an obesity drug partnership sparked buzz among Stocktwits users for the week ended March 7, 2025.


Allarity Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing personalized cancer treatments. The company is focused on development of stenoparib, a novel PARP and tankyrase inhibitor for advanced ovarian cancer patients, using its DRP technology to develop a companion diagnostic that can be used to select those patients expected to derive the greatest clinical benefit from stenoparib. Allarity Therapeutics was founded by Steen Knudsen and Thomas H. Jensen in 2004 and is headquartered in Tarpon Springs, FL.

Allarity Therapeutics Inc

Bullish Sentiment

Allarity Therapeutics, Inc. (ALLR) on Tuesday announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to its Stenoparib. Following the announcement, shares of the company more than doubled in value by Tuesday afternoon.Stenoparib is an investigational treatment for patients with advanced ovarian cancer. FDA’s Fast Track designation is intended to expedite the development and review of drugs that treat serious conditions and fill an unmet medical need. It allows for more frequent interactions with the FDA throughout the drug development process and potentially provides eligibility for accelerated approval and priority review, upon meeting relevant criteria.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/ALLR">ALLR stock</a> jumped from ‘bearish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘extremely low’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:575/61;" src="https://news.stocktwits-cdn.com/Screenshot_2025_08_26_at_12_16_43_PM_png_5d0f99e451.webp" alt="ALLR's Sentiment Meter and Message Volume as of 12:17 p.m. ET on Aug. 26, 2025 | Source: Stocktwits" width="575" height="61"><figcaption>ALLR's Sentiment Meter and Message Volume as of 12:17 p.m. ET on Aug. 26, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user expressed surprise at the rally and opined that the stock might drop to below $1 by the end of the day.<stembedurl>https://stocktwits.com/patb99/message/626594104</stembedurl>Another user stated that larger pharmaceutical companies will now be interested in the drug.<stembedurl>https://stocktwits.com/Creyedr/message/626587898</stembedurl>Allarity CEO Thomas Jensen <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/08/26/3139198/0/en/Allarity-Therapeutics-Granted-FDA-Fast-Track-Designation-for-Stenoparib-for-the-Treatment-of-Advanced-Ovarian-Cancer.html">said</a> the company is pleased with the designation. “We look forward to engaging closely with the FDA as we advance this program,” he added.US-headquartered Allarity started patient enrollment under a new mid-stage clinical trial protocol evaluating Stenoparib in advanced, recurrent, platinum-resistant, or platinum-ineligible ovarian cancer in early June 2025. Several patients have already been dosed in the study. The trial is designed to accelerate clinical development of Stenoparib. Previous mid-stage study data showed durable clinical benefit for Stenoparib.The therapy was originally developed by Eisai Co., but Allarity secured exclusive global rights for the development and commercialization.ALLR stock has gained 74% this year but has lost 59% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/regeneron-stock-rallies-after-therapy-for-autoimmune-disease-meets-late-stage-trial-goals/chsvb4wRdjv">Regeneron Stock Rallies After Therapy For Autoimmune Disease Meets Late-Stage Trial Goals: Retail Thinks Stock Might Hit An All-Time Low Soon</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

Fundamental investor

Technical trader

A mix of both

Fundamental analysis looks at earnings, valuation, and business quality, while technical analysis focuses on chart patterns, price action, and indicators, and many investors blend the two. How do you decide what to buy: fundamentals or technicals? Vote and explain your reasoning in the comments.

Current Price	$0.9719
Prev Close	$1.08
Open	$1.07
Dividend Yield	0.00%
50-Day Moving Average	$1.08
Beta	0.77
Avg. Volume	124,325.98
PE Ratio	-1.37

52-Week High	$1.84
52-Week Low	$0.7687
Market Capitalization	$17.18M
EPS (Annual)	-$0.7811
Price to Book	4.86
Revenue Per Employee	$40,000.00

Feed

News

Sentiment

Fundamentals

Info

ALLR Fundamentals